Table 3.
Frequencies and percentages of DRB1 alleles in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.
| DRB1 |
HCV patients |
Healthy controls |
PC | Responders | Nonresponders | PC |
|---|---|---|---|---|---|---|
| (n = 62) | (n = 57) | (n = 41) | (n = 21) | |||
| *01 | 2 (3.2%) | 6 (10.5%) | 0.215 | 1 (2.4%) | 1 (4.8%) | 1.000 |
| *0102 | 1 (1.6%) | 9 (15.8%) | 0.148 | 1 (2.4%) | 0 (0.0%) | 0.661 |
| *0106 | 1 (1.6%) | 1 (1.8%) | 1.000 | 1 (2.4%) | 0 (0.0%) | 0.661 |
| *03 | 13 (21.0%) | 25 (43.9%) | 0.072 | 11 (26.8%) | 2 (9.5%) | 0.187 |
| *0301 | 8 (12.9%) | 17 (29.8%) | 0.552 | 6 (14.6%) | 2 (9.5%) | 0.447 |
| *0304 | 4 (6.5%) | 12 (21.1%) | 0.112 | 2 (4.9%) | 2 (9.5%) | 0.417 |
| *0313 | 5 (8.1%) | 0 (0.0%) | 0.222 | 3 (7.3%) | 2 (9.5%) | 0.556 |
| *0328 | 8 (12.9%) | 0 (0.0%) | 0.183 | 6 (14.6%) | 2 (9.5%) | 0.447 |
| *0332 | 3 (4.8%) | 0 (0.0%) | 0.556 | 1 (2.4%) | 2 (9.5%) | 0.263 |
| *04 | 14 (22.6%) | 12 (21.1%) | 1.000 | 11 (26.8%) | 3 (14.3%) | 0.346 |
| *0403 | 3 (4.8%) | 13 (22.8%) | 0.089 | 2 (4.9%) | 1 (4.8%) | 0.737 |
| *0471 | 2 (3.2%) | 7 (12.3%) | 0.134 | 2 (4.9%) | 0 (0.0%) | 0.434 |
| *0445 | 4 (6.5%) | 9 (15.8%) | 0.212 | 2 (4.9%) | 2 (9.5%) | 0.417 |
| *07 | 22 (35.5%) | 36 (63.2%) | 0.029† | 15 (36.6%) | 7 (33.3%) | 1.000 |
| *0701 | 22 (35.5%) | 36 (63.2%) | 0.029† | 13 (31.7%) | 9 (42.9%) | 0.277 |
| *0703 | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0705 | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0706 | 4 (6.5%) | 35 (61.4%) | 0.000† | 2 (4.9%) | 2 (9.5%) | 0.417 |
| *0707 | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0708 | 6 (9.7%) | 35 (61.4%) | 0.000† | 3 (7.3%) | 3 (14.3%) | 0.325 |
| *0709 | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0710N | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0711 | 20 (32.3%) | 36 (63.2%) | 0.013† | 13 (31.7%) | 7 (33.3%) | 0.558 |
| *0712 | 4 (6.5%) | 35 (61.4%) | 0.000† | 2 (4.9%) | 2 (9.5%) | 0.417 |
| *0713 | 4 (6.5%) | 35 (61.4%) | 0.000† | 2 (4.9%) | 2 (9.5%) | 0.417 |
| *0714 | 6 (9.7%) | 35 (61.4%) | 0.000† | 3 (7.3%) | 3 (14.3%) | 0.325 |
| *08 | 4 (6.5%) | 0 (0.0%) | 0.570 | 3 (7.3%) | 1 (4.8%) | 1.000 |
| *0801 | 2 (3.2%) | 0 (0.0%) | 0.434 | 1 (2.4%) | 1 (4.8%) | 0.661 |
| *0816 | 2 (3.2%) | 0 (0.0%) | 0.434 | 1 (2.4%) | 1 (4.8%) | 0.566 |
| *0833 | 1 (1.6%) | 0 (0.0%) | 1.000 | 1 (2.4%) | 0 (0.0%) | 0.661 |
| *09 | 1 (1.6%) | 0 (0.0%) | 1.000 | 1 (2.4%) | 0 (0.0%) | 1.000 |
| *0904 | 1 (1.6%) | 0 (0.0%) | 1.000 | 1 (2.4%) | 0 (0.0%) | 0.661 |
| *0906 | 1 (1.6%) | 0 (0.0%) | 1.000 | 1 (2.4%) | 0 (0.0%) | 0.661 |
| *10 | 3 (4.8%) | 0 (0.0%) | 0.282 | 3 (7.3%) | 0 (0.0%) | 0.545 |
| *1001 | 3 (4.8%) | 0 (0.0%) | 0.282 | 3 (7.3%) | 0 (0.0%) | 0.282 |
| *11 | 12 (19.4%) | 7 (12.3%) | 0.725 | 9 (22%) | 3 (14.3%) | 0.735 |
| *1101 | 9 (14.5%) | 22 (38.6%) | 0.086 | 5 (12.2%) | 4 (19%) | 0.356 |
| *1105 | 4 (6.5%) | 8 (14%) | 0.088 | 3 (7.3%) | 1 (4.8%) | 0.583 |
| *1115 | 8 (12.9%) | 3 (5.3%) | 0.435 | 5 (12.2%) | 3 (14.3%) | 0.553 |
| *1132 | 3 (4.8%) | 3 (5.3%) | 0.868 | 3 (7.3%) | 0 (0.0%) | 0.282 |
| *1144 | 2 (3.2%) | 6 (10.5) | 0.358 | 1 (2.4%) | 1 (4.8%) | 0.566 |
| *1166 | 1 (1.6%) | 2 (3.5%) | 0.586 | 0 (0.0%) | 1 (4.8%) | 0.339 |
| *13 | 22 (35.5%) | 3 (5.3%) | 0.016† | 19 (46.3%) | 3 (14.3%) | 0.014# |
| *1301 | 7 (11.3%) | 12 (21.1%) | 0.219 | 7 (17.1%) | 0 (0%) | 0.046# |
| *1303 | 7 (11.3%) | 5 (8.8%) | 0.525 | 5 (12.2%) | 2 (9.5%) | 0.558 |
| *1361 | 7 (11.3%) | 16 (28.1%) | 0.079 | 7 (17.1%) | 0 (0%) | 0.046# |
| *1369 | 7 (11.3%) | 3 (5.3%) | 0.325 | 7 (17.1%) | 0 (0%) | 0.046# |
| *14 | 3 (4.8%) | 0 (0.0%) | 0.282 | 2 (4.9%) | 1 (4.8%) | 1.000 |
| *1401 | 1 (1.6%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 1 (4.8%) | 0.339 |
| *1475 | 1 (1.6%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 1 (4.8%) | 0.339 |
| *15 | 11 (17.7%) | 7 (12.3%) | 0.722 | 10 (24.4%) | 1 (4.8%) | 0.048# |
| *1514 | 6 (9.7%) | 3 (5.3%) | 0.476 | 5 (12.2%) | 1 (4.8%) | 0.329 |
| *1522 | 2 (3.2%) | 9 (15.8%) | 0.215 | 2 (4.9%) | 0 (0.0%) | 0.434 |
# Significant difference at PC ≤ 0.05 between responder and nonresponder patients to treatment. †Significant difference at PC ≤ 0.05 (corrected P after the Bonferroni correction) between patients and healthy group. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “n.”